Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pheno Gets Clinical Trial Authorization for PTD802 in Multiple Sclerosis
Details : PTD802 is a novel small molecule therapeutic designed to promote remyelination by inhibiting GPR17. It is being investigated for multiple sclerosis.
Product Name : PTD802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable